Amphastar Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
1.3%projected annual EPS growth
Analyst Coverage
6analysts covering
FY Revenue (est.)
$747.7Mnext fiscal year
FY EPS (est.)
$2.97next fiscal year
Monitoring Framework
Key Performance Indicators
Net Revenues Quarterly171.2M
Diluted Earnings Per Share (EPS) Quarterly0.1
Gross Profit Quarterly70.3M
Research and Development (R&D) Expenses Quarterly26.7M
Watch Items
- Erosion of Legacy Generic Products and Pricing PressuresTrigger: Further deterioration of adjusted net income margins below 20%Action: Re-evaluate commercial execution strategies and dedicated proprietary sales force allocation.
- Pipeline Transformation ProgressTrigger: Proprietary and biosimilar products falling below 80% of the pipeline mix by end of 2026Action: Review R&D spending efficiency and clinical program timelines for complex generic and peptide candidates.
Research as of 19 Jun 2026